[
  {
    "ts": "2026-02-24T01:50:00+00:00",
    "headline": "Got $5,000? Viking Therapeutics Might Be a Weight‚ÄëLoss Drug Moon Shot in the Making.",
    "summary": "Is this the best way to cash in on the weight-loss gold rush?",
    "url": "https://www.fool.com/investing/2026/02/23/got-5000-viking-therapeutics-might-be-a-weightloss/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b570b168-e5bd-3c20-8f00-9f73b1936546",
      "content": {
        "id": "b570b168-e5bd-3c20-8f00-9f73b1936546",
        "contentType": "STORY",
        "title": "Got $5,000? Viking Therapeutics Might Be a Weight‚ÄëLoss Drug Moon Shot in the Making.",
        "description": "",
        "summary": "Is this the best way to cash in on the weight-loss gold rush?",
        "pubDate": "2026-02-24T01:50:00Z",
        "displayTime": "2026-02-24T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "A person surrounded by stock monitors stands with both fists raised in the air.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3yBXzk4FUvsgR0VJ93gOsA--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3weefRt6VjSNRthUdJc8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/got-5000-viking-therapeutics-might-be-a-weightloss/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/got-5-000-viking-therapeutics-015000209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T03:12:53+00:00",
    "headline": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
    "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
    "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "16955788-3c9d-3a6f-8da1-ee8f9f9ef0d2",
      "content": {
        "id": "16955788-3c9d-3a6f-8da1-ee8f9f9ef0d2",
        "contentType": "STORY",
        "title": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
        "description": "",
        "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
        "pubDate": "2026-02-24T03:12:53Z",
        "displayTime": "2026-02-24T03:12:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T05:11:40+00:00",
    "headline": "Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs",
    "summary": "By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it",
    "url": "https://finance.yahoo.com/news/analysis-novos-stumbles-burnish-lillys-051140762.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "b90ce395-444c-3e61-9e14-abf5aa1249d9",
      "content": {
        "id": "b90ce395-444c-3e61-9e14-abf5aa1249d9",
        "contentType": "STORY",
        "title": "Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs",
        "description": "",
        "summary": "By Maggie Fick and Bhanvi Satija LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it",
        "pubDate": "2026-02-24T05:11:40Z",
        "displayTime": "2026-02-24T05:11:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/6a12d1ffc5ecbb3eb7f7e230ae800ab5",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7leTF2vBE1iGr.gatcaFvw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6a12d1ffc5ecbb3eb7f7e230ae800ab5.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d80u2lNj74jWqLsOgdWExg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6a12d1ffc5ecbb3eb7f7e230ae800ab5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-novos-stumbles-burnish-lillys-051140762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-novos-stumbles-burnish-lillys-051140762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T06:04:56+00:00",
    "headline": "Is Eli Lilly Stock Underperforming the S&P 500?",
    "summary": "Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.",
    "url": "https://www.barchart.com/story/news/378781/is-eli-lilly-stock-underperforming-the-s-p-500",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "4ab1a2b9-bc99-3c9c-8870-c1bbdd947666",
      "content": {
        "id": "4ab1a2b9-bc99-3c9c-8870-c1bbdd947666",
        "contentType": "STORY",
        "title": "Is Eli Lilly Stock Underperforming the S&P 500?",
        "description": "",
        "summary": "Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.",
        "pubDate": "2026-02-24T06:04:56Z",
        "displayTime": "2026-02-24T06:04:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/0d9ac77c949cf1810e20427fc62c5fa4",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Lilly(Eli) & Co logo on building-by Michael Vi via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rRoaSjcBmk5ZphUbBkOsTw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/0d9ac77c949cf1810e20427fc62c5fa4.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/81k.kKF6ujx761TcDBUQuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/0d9ac77c949cf1810e20427fc62c5fa4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/378781/is-eli-lilly-stock-underperforming-the-s-p-500",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-underperforming-p-060456041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T10:19:40+00:00",
    "headline": "JPM downgrades Novo on disappointing CagriSema obesity trial results, shares dip",
    "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly‚Äôs (NYSE:LLY) Zepbound.",
    "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "eb5641ba-2841-30f9-979c-5309c3cd1c16",
      "content": {
        "id": "eb5641ba-2841-30f9-979c-5309c3cd1c16",
        "contentType": "STORY",
        "title": "JPM downgrades Novo on disappointing CagriSema obesity trial results, shares dip",
        "description": "",
        "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly‚Äôs (NYSE:LLY) Zepbound.",
        "pubDate": "2026-02-24T10:19:40Z",
        "displayTime": "2026-02-24T10:19:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T10:22:00+00:00",
    "headline": "Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial",
    "summary": "Novo Nordisk said an experimental obesity drug it is jointly developing with China‚Äôs United Laboratories International Holdings helped patients lose weight in a midstage clinical trial in China.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-united-laboratories-say-new-obesity-drug-helps-patients-lose-weight-in-trial-99d136d5?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ba156d1b-2ea6-3e10-92e5-8f3496646dfe",
      "content": {
        "id": "ba156d1b-2ea6-3e10-92e5-8f3496646dfe",
        "contentType": "STORY",
        "title": "Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial",
        "description": "",
        "summary": "Novo Nordisk said an experimental obesity drug it is jointly developing with China‚Äôs United Laboratories International Holdings helped patients lose weight in a midstage clinical trial in China.",
        "pubDate": "2026-02-24T10:22:00Z",
        "displayTime": "2026-02-24T10:22:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ba156d1b-2ea6-3e10-92e5-8f3496646dfe/novo-nordisk-united.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d9b06aabbde29b5f0c437c6bdfdb3e61",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9YVuT0Rj7ggNZ2ogR0jpg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d9b06aabbde29b5f0c437c6bdfdb3e61.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8FBR6XJBqydlWK.U6rFtFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d9b06aabbde29b5f0c437c6bdfdb3e61.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-united-laboratories-say-new-obesity-drug-helps-patients-lose-weight-in-trial-99d136d5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T10:19:40+00:00",
    "headline": "Novo Nordisk selloff continues as stock gets hit with rating downgrades",
    "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly‚Äôs (NYSE:LLY) Zepbound.",
    "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "eb5641ba-2841-30f9-979c-5309c3cd1c16",
      "content": {
        "id": "eb5641ba-2841-30f9-979c-5309c3cd1c16",
        "contentType": "STORY",
        "title": "Novo Nordisk selloff continues as stock gets hit with rating downgrades",
        "description": "",
        "summary": "Investing.com -- JPMorgan downgraded Novo Nordisk (CSE:NOVOb) (NYSE:NVO) to Neutral from Overweight after disappointing late-stage REDEFINE-4 results for its obesity drug CagriSema showed weaker-than-expected competitiveness versus Eli Lilly‚Äôs (NYSE:LLY) Zepbound.",
        "pubDate": "2026-02-24T10:19:40Z",
        "displayTime": "2026-02-24T10:19:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm-downgrades-novo-disappointing-cagrisema-101940459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T13:01:22+00:00",
    "headline": "Novo to cut Ozempic and Wegovy prices amid intense competition",
    "summary": "Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.",
    "url": "https://www.usatoday.com/story/money/2026/02/24/novo-slashes-ozempic-wegovy-prices-effective-jan-1-2027/88826854007/",
    "source": "USA TODAY",
    "provider": "yfinance",
    "raw": {
      "id": "448d3877-233a-3d3f-ab73-de5ed9ee2925",
      "content": {
        "id": "448d3877-233a-3d3f-ab73-de5ed9ee2925",
        "contentType": "STORY",
        "title": "Novo to cut Ozempic and Wegovy prices amid intense competition",
        "description": "",
        "summary": "Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.",
        "pubDate": "2026-02-24T13:01:22Z",
        "displayTime": "2026-02-24T13:01:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/usa_today_money_325/1fcbc908a1a57478c6e1959d513dae48",
          "originalWidth": 1800,
          "originalHeight": 1200,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GM7Z7y.2utJrZUjmafiG3Q--~B/aD0xMjAwO3c9MTgwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/usa_today_money_325/1fcbc908a1a57478c6e1959d513dae48.cf.webp",
              "width": 1800,
              "height": 1200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MzFbGWKDulhTc7dpbULT5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/usa_today_money_325/1fcbc908a1a57478c6e1959d513dae48.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "USA TODAY",
          "url": "https://www.usatoday.com/money/"
        },
        "canonicalUrl": {
          "url": "https://www.usatoday.com/story/money/2026/02/24/novo-slashes-ozempic-wegovy-prices-effective-jan-1-2027/88826854007/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-cut-ozempic-wegovy-prices-130122241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T11:59:00+00:00",
    "headline": "Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors.",
    "summary": "Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.",
    "url": "https://www.barrons.com/articles/hims-hers-earnings-stock-price-8c55cdf6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "54ece237-5667-35ac-b3be-4964f9e6ee47",
      "content": {
        "id": "54ece237-5667-35ac-b3be-4964f9e6ee47",
        "contentType": "STORY",
        "title": "Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors.",
        "description": "",
        "summary": "Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.",
        "pubDate": "2026-02-24T11:59:00Z",
        "displayTime": "2026-02-24T11:59:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/54ece237-5667-35ac-b3be-4964f9e6ee47/hims-hers-stock-drops-why.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/0d923cd33e4a6b4b79f834cacc7d50bb",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wC8UE_pFeVOPBVCZ89CUyA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/0d923cd33e4a6b4b79f834cacc7d50bb.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ey.YvUwTiGx7hYgLsOB.kA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/0d923cd33e4a6b4b79f834cacc7d50bb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/hims-hers-earnings-stock-price-8c55cdf6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO.NE"
            },
            {
              "symbol": "NVO.TO"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T11:52:00+00:00",
    "headline": "Markets Must Look Past the AI Panic. Jamie Dimon Offers Some Hope.",
    "summary": "Waller calls March rate decision a coin flip, a viral online post slams stocks, tariff refunds are in play, and more news to start your day.",
    "url": "https://www.barrons.com/articles/stock-market-ai-panic-things-to-know-today-3b1ea14f?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ef771413-d221-318b-8e69-beb2086b7960",
      "content": {
        "id": "ef771413-d221-318b-8e69-beb2086b7960",
        "contentType": "STORY",
        "title": "Markets Must Look Past the AI Panic. Jamie Dimon Offers Some Hope.",
        "description": "",
        "summary": "Waller calls March rate decision a coin flip, a viral online post slams stocks, tariff refunds are in play, and more news to start your day.",
        "pubDate": "2026-02-24T11:52:00Z",
        "displayTime": "2026-02-24T11:52:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ef771413-d221-318b-8e69-beb2086b7960/markets-must-look-past-the-ai.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b9e3230893b040d5dbc63de60521d5d6",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xcsq_W.tcLlj7ejBqXP70A--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b9e3230893b040d5dbc63de60521d5d6.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YvlBm16WHcSjLM1lKpSh0g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b9e3230893b040d5dbc63de60521d5d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-market-ai-panic-things-to-know-today-3b1ea14f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBM"
            },
            {
              "symbol": "FDX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "ANTH.PVT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T14:15:04+00:00",
    "headline": "Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound",
    "summary": "The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087825/novo-nordisk-downgraded-by-leading-banks-as-cagrisema-trial-flops-against-zepbound-1087825.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "c18d7c37-1caf-3f36-a091-03309952efe8",
      "content": {
        "id": "c18d7c37-1caf-3f36-a091-03309952efe8",
        "contentType": "STORY",
        "title": "Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound",
        "description": "",
        "summary": "The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide...",
        "pubDate": "2026-02-24T14:15:04Z",
        "displayTime": "2026-02-24T14:15:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/10074dfc458328725efabc1722b74292",
          "originalWidth": 960,
          "originalHeight": 720,
          "caption": "Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tkCf7R.EtNfx2WuaN9LWpA--~B/aD03MjA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/10074dfc458328725efabc1722b74292.cf.webp",
              "width": 960,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uBvQpFcbeuZixpQWS8fYdw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/10074dfc458328725efabc1722b74292.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087825/novo-nordisk-downgraded-by-leading-banks-as-cagrisema-trial-flops-against-zepbound-1087825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-downgraded-leading-banks-141504518.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T13:21:00+00:00",
    "headline": "Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping.",
    "summary": "The Danish drugmaker released a promising update about a trial in China, but that didn‚Äôt end a rough run for shares.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-ozempic-wegovy-prices-eli-lilly-86cda8ea?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "0d730ac9-82b1-3495-80b5-e3ce44ef2b64",
      "content": {
        "id": "0d730ac9-82b1-3495-80b5-e3ce44ef2b64",
        "contentType": "STORY",
        "title": "Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping.",
        "description": "",
        "summary": "The Danish drugmaker released a promising update about a trial in China, but that didn‚Äôt end a rough run for shares.",
        "pubDate": "2026-02-24T13:21:00Z",
        "displayTime": "2026-02-24T13:21:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0d730ac9-82b1-3495-80b5-e3ce44ef2b64/novo-nordisk-is-cutting.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/37de4469f4e99a928c70213201797725",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s5.RFUGk_cPfKJROesXERQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/37de4469f4e99a928c70213201797725.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9Lwhl_wkBqsQ.2_a0DPjoA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/37de4469f4e99a928c70213201797725.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-ozempic-wegovy-prices-eli-lilly-86cda8ea?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "3933.HK"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T13:13:47+00:00",
    "headline": "Eli Lilly falls 2% on Novo Nordisk price cut plans",
    "summary": "Investing.com -- Eli Lilly (NYSE:LLY) shares fell 2.2% Tuesday morning following a Wall Street Journal report that rival Novo Nordisk plans to slash U.S. list prices for its weight-loss and diabetes drugs Ozempic and Wegovy by up to 50%. Novo Nordisk shares were lower by 3%.",
    "url": "https://finance.yahoo.com/news/eli-lilly-falls-2-novo-131347190.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "e2a9d3e1-fad2-3e6f-bf12-0321fb8498ce",
      "content": {
        "id": "e2a9d3e1-fad2-3e6f-bf12-0321fb8498ce",
        "contentType": "STORY",
        "title": "Eli Lilly falls 2% on Novo Nordisk price cut plans",
        "description": "",
        "summary": "Investing.com -- Eli Lilly (NYSE:LLY) shares fell 2.2% Tuesday morning following a Wall Street Journal report that rival Novo Nordisk plans to slash U.S. list prices for its weight-loss and diabetes drugs Ozempic and Wegovy by up to 50%. Novo Nordisk shares were lower by 3%.",
        "pubDate": "2026-02-24T13:13:47Z",
        "displayTime": "2026-02-24T13:13:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-falls-2-novo-131347190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-falls-2-novo-131347190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T12:53:47+00:00",
    "headline": "Stocks to Watch Tuesday: FedEx, Home Depot, Novo Nordisk",
    "summary": "üîé FedEx (FDX): The parcel-delivery company filed a lawsuit seeking a full refund plus interest for what it paid in levies stemming from President Trump‚Äôs tariffs enacted last year. ‚ÜóÔ∏è Home Depot (HD): The home-improvement retailer's quarterly results topped expectations, despite profit falling.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stocks-to-watch-tuesday-fedex-home-depot-apple-DtP9rE90U2lgvL3YTPpG?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "0bdfb26c-185a-3467-9f1b-20db81eec6bc",
      "content": {
        "id": "0bdfb26c-185a-3467-9f1b-20db81eec6bc",
        "contentType": "STORY",
        "title": "Stocks to Watch Tuesday: FedEx, Home Depot, Novo Nordisk",
        "description": "",
        "summary": "üîé FedEx (FDX): The parcel-delivery company filed a lawsuit seeking a full refund plus interest for what it paid in levies stemming from President Trump‚Äôs tariffs enacted last year. ‚ÜóÔ∏è Home Depot (HD): The home-improvement retailer's quarterly results topped expectations, despite profit falling.",
        "pubDate": "2026-02-24T12:53:47Z",
        "displayTime": "2026-02-24T12:53:47Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0bdfb26c-185a-3467-9f1b-20db81eec6bc/stocks-to-watch-tuesday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/793f27c879e055538c26545ddd1afdd9",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oAeXQOx2GKuikk21sn4YlA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/793f27c879e055538c26545ddd1afdd9.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WZYyiuOFJ.8bgM48Y9oNKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/793f27c879e055538c26545ddd1afdd9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stocks-to-watch-tuesday-fedex-home-depot-apple-DtP9rE90U2lgvL3YTPpG?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "1211.HK"
            },
            {
              "symbol": "81211.HK"
            },
            {
              "symbol": "FDX"
            },
            {
              "symbol": "HD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "HIMS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T12:30:00+00:00",
    "headline": "Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%",
    "summary": "The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-to-cut-u-s-list-prices-for-ozempic-wegovy-by-up-to-50-f1b038fb?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "e6c62423-d75f-3a95-acf9-c2c9fecb967a",
      "content": {
        "id": "e6c62423-d75f-3a95-acf9-c2c9fecb967a",
        "contentType": "STORY",
        "title": "Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%",
        "description": "",
        "summary": "The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.",
        "pubDate": "2026-02-24T12:30:00Z",
        "displayTime": "2026-02-24T12:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e6c62423-d75f-3a95-acf9-c2c9fecb967a/novo-nordisk-to-cut-u-s-list.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/14a266b89737616c94cfc7a6e4fe9345",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ehgcyS89vJeNWTcOZ2CkCg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/14a266b89737616c94cfc7a6e4fe9345.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8fML5G4usWXPPeJ4jpHAaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/14a266b89737616c94cfc7a6e4fe9345.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-to-cut-u-s-list-prices-for-ozempic-wegovy-by-up-to-50-f1b038fb?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T12:22:00+00:00",
    "headline": "Company News for Feb 24, 2026",
    "summary": "Companies In The Article Are: NVO,LLY,DASH,PYPL,VRE",
    "url": "https://finance.yahoo.com/news/company-news-feb-24-2026-122200223.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "aed182a7-e34b-3587-ab98-a89e3a84f502",
      "content": {
        "id": "aed182a7-e34b-3587-ab98-a89e3a84f502",
        "contentType": "STORY",
        "title": "Company News for Feb 24, 2026",
        "description": "",
        "summary": "Companies In The Article Are: NVO,LLY,DASH,PYPL,VRE",
        "pubDate": "2026-02-24T12:22:00Z",
        "displayTime": "2026-02-24T12:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/0972ed26da02b91851ed074b35adf13e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3oLLbROqXrsOrmL.rIWq7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0972ed26da02b91851ed074b35adf13e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HCXJw0rh5X.zStJ.KYW9Ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0972ed26da02b91851ed074b35adf13e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/company-news-feb-24-2026-122200223.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/company-news-feb-24-2026-122200223.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PYPL"
            },
            {
              "symbol": "DASH"
            },
            {
              "symbol": "VRE"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T15:08:16+00:00",
    "headline": "Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027",
    "summary": "Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.",
    "url": "https://www.cbsnews.com/news/wegovy-ozempic-novo-nordisk-price-cut-january-2027/?ftag=YHF4eb9d17",
    "source": "CBS News",
    "provider": "yfinance",
    "raw": {
      "id": "8b4879ad-e88a-3f3e-ac0c-93f5e9c854d8",
      "content": {
        "id": "8b4879ad-e88a-3f3e-ac0c-93f5e9c854d8",
        "contentType": "STORY",
        "title": "Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027",
        "description": "",
        "summary": "Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.",
        "pubDate": "2026-02-24T15:08:16Z",
        "displayTime": "2026-02-24T15:08:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cbs_news_897/0fed247c1ea7db748d38ad86334cbb6f",
          "originalWidth": 5400,
          "originalHeight": 3600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3MR7CoDUyRVgvXGrkH2JkA--~B/aD0zNjAwO3c9NTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/cbs_news_897/0fed247c1ea7db748d38ad86334cbb6f.cf.webp",
              "width": 5400,
              "height": 3600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K1wpBOGOLaN3sdW0dfEGOQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cbs_news_897/0fed247c1ea7db748d38ad86334cbb6f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CBS News",
          "url": "https://www.cbsnews.com/"
        },
        "canonicalUrl": {
          "url": "https://www.cbsnews.com/news/wegovy-ozempic-novo-nordisk-price-cut-january-2027/?ftag=YHF4eb9d17",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-slash-wegovy-ozempic-150816928.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T14:18:56+00:00",
    "headline": "Stock in Rivals Novo Nordisk and Eli Lilly Slips",
    "summary": "Novo Nordisk (NVO), (DK:NOVO.B) plans to slash U.S. list prices for its popular Wegovy and Ozempic by up to half starting next year. The Danish drugmaker a day earlier disclosed that its next-generation obesity treatment failed to beat Eli Lilly's Zepbound in a head-to-head study, though, and its Danish-listed shares fell around 2.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stock-in-rivals-novo-nordisk-and-eli-lilly-slips-2UJiwuaHsI1YiFkEifNK?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "3895abac-cae0-3d1c-8ef5-f387c5a51129",
      "content": {
        "id": "3895abac-cae0-3d1c-8ef5-f387c5a51129",
        "contentType": "STORY",
        "title": "Stock in Rivals Novo Nordisk and Eli Lilly Slips",
        "description": "",
        "summary": "Novo Nordisk (NVO), (DK:NOVO.B) plans to slash U.S. list prices for its popular Wegovy and Ozempic by up to half starting next year. The Danish drugmaker a day earlier disclosed that its next-generation obesity treatment failed to beat Eli Lilly's Zepbound in a head-to-head study, though, and its Danish-listed shares fell around 2.",
        "pubDate": "2026-02-24T14:18:56Z",
        "displayTime": "2026-02-24T14:18:56Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3895abac-cae0-3d1c-8ef5-f387c5a51129/stock-in-rivals-novo-nordisk.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/47b652e80ad37a1974908c3efe66ae24",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l8FfqJO07R4YyAwDfwYcgA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/47b652e80ad37a1974908c3efe66ae24.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Sft10LIyh8sk1uL_DvQjA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/47b652e80ad37a1974908c3efe66ae24.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stock-in-rivals-novo-nordisk-and-eli-lilly-slips-2UJiwuaHsI1YiFkEifNK?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T14:02:22+00:00",
    "headline": "Novo Nordisk halves US price of weight-loss drug",
    "summary": "Novo Nordisk is halving the US list price of its most popular weight-loss drug as the Danish drugmaker struggles to compete with rival Eli Lilly...",
    "url": "https://finance.yahoo.com/news/novo-nordisk-halves-us-price-140222058.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "06517951-1520-3154-867f-f9bf1454fdce",
      "content": {
        "id": "06517951-1520-3154-867f-f9bf1454fdce",
        "contentType": "STORY",
        "title": "Novo Nordisk halves US price of weight-loss drug",
        "description": "",
        "summary": "Novo Nordisk is halving the US list price of its most popular weight-loss drug as the Danish drugmaker struggles to compete with rival Eli Lilly...",
        "pubDate": "2026-02-24T14:02:22Z",
        "displayTime": "2026-02-24T14:02:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-halves-us-price-140222058.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-halves-us-price-140222058.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T14:02:00+00:00",
    "headline": "IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?",
    "summary": "With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?",
    "url": "https://finance.yahoo.com/news/iova-vs-rigl-small-cap-140200918.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "237e9c24-ef45-381e-beaa-67f4fedf7d35",
      "content": {
        "id": "237e9c24-ef45-381e-beaa-67f4fedf7d35",
        "contentType": "STORY",
        "title": "IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?",
        "description": "",
        "summary": "With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?",
        "pubDate": "2026-02-24T14:02:00Z",
        "displayTime": "2026-02-24T14:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/iova-vs-rigl-small-cap-140200918.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/iova-vs-rigl-small-cap-140200918.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IOVA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RIGL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T13:13:47+00:00",
    "headline": "Eli Lilly slips on Novo Nordisk price cut plans",
    "summary": "Investing.com -- Eli Lilly (NYSE:LLY) shares slid about 2% on Tuesday following a Wall Street Journal report that rival Novo Nordisk plans to slash U.S. list prices for its weight-loss and diabetes drugs Ozempic and Wegovy by up to 50%.",
    "url": "https://finance.yahoo.com/news/eli-lilly-falls-2-novo-131347190.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "e2a9d3e1-fad2-3e6f-bf12-0321fb8498ce",
      "content": {
        "id": "e2a9d3e1-fad2-3e6f-bf12-0321fb8498ce",
        "contentType": "STORY",
        "title": "Eli Lilly slips on Novo Nordisk price cut plans",
        "description": "",
        "summary": "Investing.com -- Eli Lilly (NYSE:LLY) shares slid about 2% on Tuesday following a Wall Street Journal report that rival Novo Nordisk plans to slash U.S. list prices for its weight-loss and diabetes drugs Ozempic and Wegovy by up to 50%.",
        "pubDate": "2026-02-24T13:13:47Z",
        "displayTime": "2026-02-24T13:13:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-falls-2-novo-131347190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-falls-2-novo-131347190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T15:43:57+00:00",
    "headline": "Novo Nordisk, Eli Lilly Stocks Drop on Wegovy Maker's Price-Cut Plan",
    "summary": "Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity and diabetes treatments by up to half next year.    The Wegovy and Ozempic maker's American depositary receipts (NVO) fell more than 2% in morning trade, extending a multiday slide.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stock-in-rivals-novo-nordisk-and-eli-lilly-slips-2UJiwuaHsI1YiFkEifNK?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "3895abac-cae0-3d1c-8ef5-f387c5a51129",
      "content": {
        "id": "3895abac-cae0-3d1c-8ef5-f387c5a51129",
        "contentType": "STORY",
        "title": "Novo Nordisk, Eli Lilly Stocks Drop on Wegovy Maker's Price-Cut Plan",
        "description": "",
        "summary": "Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity and diabetes treatments by up to half next year.    The Wegovy and Ozempic maker's American depositary receipts (NVO) fell more than 2% in morning trade, extending a multiday slide.",
        "pubDate": "2026-02-24T15:43:57Z",
        "displayTime": "2026-02-24T15:43:57Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3895abac-cae0-3d1c-8ef5-f387c5a51129/novo-nordisk-eli-lilly.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stock-in-rivals-novo-nordisk-and-eli-lilly-slips-2UJiwuaHsI1YiFkEifNK?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T13:01:55+00:00",
    "headline": "Is Johnson & Johnson Stock Outperforming the Nasdaq?",
    "summary": "Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock‚Äôs prospects.",
    "url": "https://www.barchart.com/story/news/385979/is-johnson-johnson-stock-outperforming-the-nasdaq",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "8bbd7aee-8451-3ab6-9416-9fc8afc27f88",
      "content": {
        "id": "8bbd7aee-8451-3ab6-9416-9fc8afc27f88",
        "contentType": "STORY",
        "title": "Is Johnson & Johnson Stock Outperforming the Nasdaq?",
        "description": "",
        "summary": "Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock‚Äôs prospects.",
        "pubDate": "2026-02-24T13:01:55Z",
        "displayTime": "2026-02-24T13:01:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811",
          "originalWidth": 1254,
          "originalHeight": 836,
          "caption": "Johnson & Johnson location sign-by JHVEPhoto via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WxItDWVtCIzt2FJ3UmpHSw--~B/aD04MzY7dz0xMjU0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811.cf.webp",
              "width": 1254,
              "height": 836,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QikPTc9YwcWzMCIsLH.J6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/385979/is-johnson-johnson-stock-outperforming-the-nasdaq",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-stock-outperforming-nasdaq-130155744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "$NASX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T17:26:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Novo Nordisk, Chinese pharma and biotech firms and more in the latest Market Talks covering Health Care.",
    "url": "https://www.wsj.com/business/health-care-roundup-market-talk-c7bdebd9?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "4d26fff2-5848-3b7c-a245-171e3a8748f5",
      "content": {
        "id": "4d26fff2-5848-3b7c-a245-171e3a8748f5",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Novo Nordisk, Chinese pharma and biotech firms and more in the latest Market Talks covering Health Care.",
        "pubDate": "2026-02-24T17:26:00Z",
        "displayTime": "2026-02-24T17:26:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4d26fff2-5848-3b7c-a245-171e3a8748f5/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/cf424bcc23dd89e2ecb9a455fae7790a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/boe5DFFJdjfQK3lIHFKNpg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/cf424bcc23dd89e2ecb9a455fae7790a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/digV8uTrj_8vdBaYyi2clQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/cf424bcc23dd89e2ecb9a455fae7790a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/health-care-roundup-market-talk-c7bdebd9?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T17:00:00+00:00",
    "headline": "Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026",
    "summary": "LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.",
    "url": "https://finance.yahoo.com/news/lilly-vs-novo-nordisk-obesity-170000484.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3dca264e-fd02-39ce-af39-12a66aa695cc",
      "content": {
        "id": "3dca264e-fd02-39ce-af39-12a66aa695cc",
        "contentType": "STORY",
        "title": "Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026",
        "description": "",
        "summary": "LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.",
        "pubDate": "2026-02-24T17:00:00Z",
        "displayTime": "2026-02-24T17:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-vs-novo-nordisk-obesity-170000484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-vs-novo-nordisk-obesity-170000484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T15:43:57+00:00",
    "headline": "Novo Nordisk, Eli Lilly Stocks Drop on Wegovy Maker‚Äôs Price-Cut Plan",
    "summary": "Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity and diabetes treatments by up to half next year.    The Wegovy and Ozempic maker's American depositary receipts (NVO) fell more than 2%, extending a multiday slide.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stock-in-rivals-novo-nordisk-and-eli-lilly-slips-2UJiwuaHsI1YiFkEifNK?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "3895abac-cae0-3d1c-8ef5-f387c5a51129",
      "content": {
        "id": "3895abac-cae0-3d1c-8ef5-f387c5a51129",
        "contentType": "STORY",
        "title": "Novo Nordisk, Eli Lilly Stocks Drop on Wegovy Maker‚Äôs Price-Cut Plan",
        "description": "",
        "summary": "Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity and diabetes treatments by up to half next year.    The Wegovy and Ozempic maker's American depositary receipts (NVO) fell more than 2%, extending a multiday slide.",
        "pubDate": "2026-02-24T15:43:57Z",
        "displayTime": "2026-02-24T15:43:57Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3895abac-cae0-3d1c-8ef5-f387c5a51129/novo-nordisk-eli-lilly.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-24-2026/card/stock-in-rivals-novo-nordisk-and-eli-lilly-slips-2UJiwuaHsI1YiFkEifNK?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T19:48:38+00:00",
    "headline": "Novo Nordisk Unveils Up to 50% US Price Cut for Wegovy, Ozempic",
    "summary": "Drugmaker sets $675 monthly list price starting Jan. 1, as shares fall 2.8% and stock slides 19% after CagriSema results.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-unveils-50-us-194838556.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "7aee4bf3-a888-31b5-b39d-2daedd77b62d",
      "content": {
        "id": "7aee4bf3-a888-31b5-b39d-2daedd77b62d",
        "contentType": "STORY",
        "title": "Novo Nordisk Unveils Up to 50% US Price Cut for Wegovy, Ozempic",
        "description": "",
        "summary": "Drugmaker sets $675 monthly list price starting Jan. 1, as shares fall 2.8% and stock slides 19% after CagriSema results.",
        "pubDate": "2026-02-24T19:48:38Z",
        "displayTime": "2026-02-24T19:48:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-unveils-50-us-194838556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-unveils-50-us-194838556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T19:47:22+00:00",
    "headline": "Eli Lilly Drops After Novo Nordisk Unleashes Massive GLP-1 Price Cuts",
    "summary": "Novo Nordisk Triggers Market Jolt With Aggressive Drug Price Reduction Plan",
    "url": "https://finance.yahoo.com/news/eli-lilly-drops-novo-nordisk-194722337.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "400301a9-591e-3d7f-872d-1b0e769a50f7",
      "content": {
        "id": "400301a9-591e-3d7f-872d-1b0e769a50f7",
        "contentType": "STORY",
        "title": "Eli Lilly Drops After Novo Nordisk Unleashes Massive GLP-1 Price Cuts",
        "description": "",
        "summary": "Novo Nordisk Triggers Market Jolt With Aggressive Drug Price Reduction Plan",
        "pubDate": "2026-02-24T19:47:22Z",
        "displayTime": "2026-02-24T19:47:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-drops-novo-nordisk-194722337.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-drops-novo-nordisk-194722337.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]